Search

everythinglearnresearchcommunity

for

Search:↓

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Two siblings both had a rare case of alopecia areata at the same time.

Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Alopecia areata in US adolescents leads to significant healthcare costs and usage.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.

The SARS-CoV-2 vaccine may be linked to triggering autoimmune conditions like Alopecia Areata.

AB+ blood group is more common in alopecia areata patients.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Trichoscopy helped diagnose and treat a woman with two different types of hair loss.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Diphenylcyclopropenone is effective for treating alopecia areata but has a high relapse rate.

Platelet-rich plasma and microneedling could potentially help hair regrowth in alopecia areata patients, but more research is needed.

0.05% Betamethasone Dipropionate is the most effective topical treatment for alopecia areata.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The study suggests that hypothyroidism may cause alopecia areata.

Both treatments for alopecia areata showed similar modest effectiveness.

Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.

Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.